



Xencor to Present at Upcoming Investor Conferences

August 2, 2021

MONROVIA, Calif.--(BUSINESS WIRE)--Aug. 2, 2021-- Xencor, Inc. (NASDAQ:XCOR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate in the following upcoming investor events and conferences:

- **Bernstein CD28 Day**
Presentation: Monday, August 9, 1:00 p.m. ET (10:00 a.m. PT)
- **2021 Webdush PacGrow Healthcare Virtual Conference**
Panel: Tuesday, August 10, 1:10 p.m. ET (10:10 a.m. PT)
- **BTIG Virtual Biotechnology Conference 2021**
Presentation: Tuesday, August 10, 3:30 p.m. ET (12:30 p.m. PT)
- **Canaccord Genuity 41st Annual Growth Conference**
Presentation: Wednesday, August 11, 4:30 p.m. ET (1:30 p.m. PT)
- **Piper Sandler Virtual West Coast Bus Tour**
Presentation: Thursday, August 12, 4:00 p.m. ET (1:00 p.m. PT)

A webcast of the presentation at the Canaccord conference will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. Following the webcast, a replay will be archived on the website approximately for at least 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 22 candidates engineered with Xencor's XmAb[®] technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210802005699/en/): <https://www.businesswire.com/news/home/20210802005699/en/>

Charles Liles
cliles@xencor.com

Media Contact
Jason I. Spark
Canale Communications
619-849-6005
jason@canalecomm.com

Source: Xencor, Inc.